Recombinant human erythropoietin shortens the uraemic bleeding time without causing intravascular haemostatic activation
1990
Abstract Blood rheology and haemostasis have been investigated in 8 haemodialysis patients during treatment with recombinant human erythropoietin (rHuEPO). The aim was to elucidate the mechanism by which rHuEPO improves haemostasis, and to determine whether rHuEPO promotes intravascular coagulation. Investigations were performed before, and after 3 months of treatment. Haemoglobin and haematocrit rose significantly after rHuEPO (p
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
32
References
41
Citations
NaN
KQI